Clinical Trials
4 trialsNCT04316546 2026-05-22
MK-7075 (Miransertib) in Proteus Syndrome
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT02594215 2022-06-30
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02476955 2020-09-30
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT01473095 2017-10-23
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed